Q32 Bio (QTTB) Net Income (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Net Income of -$16.1 million for Q1 2026, down 45.83% year-over-year from -$29.7 million in Q1 2025, and down 127.87% quarter-over-quarter from $57.7 million in Q4 2025.
Q32 Bio (QTTB) Net Income (2017 - 2026) Analysis & Trends
Q32 Bio's Net Income history runs 10 years deep, the most recent figure standing at -$16.1 million for Q1 2026.
- In Q1 2026, Net Income fell 45.83% year-over-year to -$16.1 million; the TTM figure through Mar 2026 stood at $24.8 million (up 142.45% YoY), while the FY2025 annual figure was $29.8 million, up 164.68% from the prior year.
- Net Income for Q1 2026 stood at -$16.1 million, down from $57.7 million in the prior quarter.
- The five-year high for Net Income was $92.7 million in Q1 2022, with the low at -$34.6 million in Q4 2022.
- The 5-year median for Net Income is -$14.0 million (2023), against an average of -$5.2 million.
- The sharpest annual moves came in 2022 and 2025: Net Income soared 8738.96% in 2022, then slumped 1015.44% in 2025.
- Q32 Bio's Net Income stood at -$34.6 million in 2022, then gained by 21.48% to -$27.1 million in 2023, then surged by 47.7% to -$14.2 million in 2024, then surged by 506.86% to $57.7 million in 2025, then sank by 127.87% to -$16.1 million in 2026.
- Business Quant data shows QTTB's Net Income at -$16.1 million in Q1 2026, $57.7 million in Q4 2025, and -$7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | -30.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.73 Mn |
| Mar 31, 2026 | -16.09 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.56 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.70 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -30.61 Mn |